Twitter LinkedIn YouTube iTune Podcast Google Podcasts Spotify

Hemostemix Inc.

Disclaimer: All stock information on InvestorIntel.com is currently being fed from multiple sources and is updated automatically every 10-minutes. The information on this site is for information purposes only and InvestorIntel Corp. is neither responsible nor liable for the accuracy of this data.

InvestorIntel Features on Hemostemix Inc.

Fully funded with strong IP Portfolio, Hemostemix marches forward towards FDA Phase II Clinical Trial Completion

Hemostemix Inc. (TSXV: HEM | OTC: HMTXF) continues to move forward with its FDA Phase II clinical trial program of […]

Hemostemix CEO on ACP’s Response to Ischemia in the Circulatory System

In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM […]

Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy

In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM […]

Company Overview

Team | Website

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

News Releases

View All News

Twitter LinkedIn YouTube Amazon Alexa iTune Podcast Google Podcasts Spotify